In 2012, an estimated 782 500 new cases and 745 000 deaths by liver cancer occurred worldwide ([@bib20]). The incidence of liver cancer among all cancer is fifth and ninth in men and women, respectively ([@bib20]). Most primary liver cancers occurring worldwide are hepatocellular carcinoma (HCC) ([@bib20]). Compared with the low incidence of liver cancer, mortality of liver cancer is relatively high. Liver cancer is the second leading cause of cancer death in men and sixth common cause of cancer death in women ([@bib20]). The prognosis of HCC is poor as considerable numbers of patients with HCC is diagnosed at advanced stages and have concurrent liver failure ([@bib19]).

HCC is highly refractory to conventional systemic chemotherapy ([@bib22]). In advanced disease, molecular targeted agent sorafenib has shown efficacy and is the current standard of care ([@bib15]; [@bib9]). Recently, a number of studies investigated the efficacy of novel molecular targeted agents such as sunitinib, everolimus, brivanib, linifanib, and ramucirumab in advanced HCC ([@bib10]; [@bib12]; [@bib13]; [@bib23]; [@bib8]). However, all study results turned out to be negative in both first line and second line settings. Recently, regorafenib has shown efficacy in HCC patients who progressed on sorafenib ([@bib3]). At present, sorafenib is the only systemic agent approved for advanced HCC and regorafenib may be an option after failure of sorafenib.

Overall survival (OS) is the most important endpoint in oncology clinical trials. However, OS can be affected by sequential treatments and requires longer follow-up duration compared with the surrogate endpoints. Using surrogate endpoints may facilitate earlier analysis of study data and provide more direct measure of study efficacy, eliminating the impact of sequential treatments. Progression-free survival (PFS) and disease-free survival is suggested as an appropriate surrogate endpoint in phase II or III clinical trial conducted in solid tumour patients. The correlation between surrogate endpoints and OS has been validated in many types of cancer, including breast cancer, colorectal cancer, and lung cancer ([@bib7]; [@bib18]; [@bib17]; [@bib1]; [@bib16]). However, there is no study that has evaluated the correlation between surrogate endpoints and OS in advanced HCC.

Many trials are being carried out to better understand the molecular pathogenesis of HCC and to develop novel treatments for HCC. However, the design of clinical trials of HCC is difficult as it is a heterogeneous disease in terms of aetiology. The leading cause of HCC in Asia and Africa is hepatitis B virus (HBV) compared with hepatitis C virus (HCV) in Europe and North America ([@bib2]). Non-viral causes such as alcoholic cirrhosis and many inherited metabolism disease (Wilson\'s disease, hemochromatosis, etc.) can also develop HCC ([@bib11]). Heterogeneous population included in the HCC clinical trial can confound the study results. In addition, many patients with HCC have concurrent liver failure ([@bib14]). As death resulting from liver failure can confound the potential benefits of effective drug, time to progression (TTP) has been suggested as a reliable surrogate endpoints in HCC compared with PFS ([@bib14]). However, there is no evidence whether TTP is a reliable surrogate marker in HCC.

The primary purpose of this study was to evaluate the relationship between TTP and OS in advanced HCC.

Materials and methods
=====================

Literature review, selection criteria and data extraction
---------------------------------------------------------

Randomised controlled phase III clinical trials of HCC that evaluated the efficacy of systemic chemotherapy or molecular targeted therapy were identified through PubMed and Embase. Two authors (DWL and KHL) independently carried out a comprehensive systemic search. The main keywords used for the search were 'hepatocellular carcinoma\', 'advanced or metastatic\' and 'randomized controlled trial\'. Article published from January 1, 2008 through July 1, 2015 were included. Eligibility criteria for the included studies were: randomised controlled phase III trials, studies involving patients with advanced HCC and studies evaluating the role of systemic chemotherapy or molecular targeted agent, studies with TTP data. When duplicate publications were identified, we included the most recent article. Studies assessing the efficacy of systemic therapies in combination to loco-regional therapies were excluded.

For each included study, two authors (DWL and KHL) abstracted data for study design, study phase, study period, institution, main inclusion and exclusion criteria, treatment regimen, line of treatment, sample size per treatment arm, baseline characteristics of study patients and data on TTP and OS. All data and analyses were based on all randomly assigned patients using the intention-to-treat approach. Survival data (PFS, TTP and OS) were collected in median data for each trial arms. Hazard ratios (HRs) of control to experimental arm for these endpoints were extracted. When available, confidence intervals (CI) were also collected to evaluate the variations in median outcome.

Statistical analysis
--------------------

The primary objective of this study was to investigate whether TTP could be used as a surrogate marker for OS in advanced HCC patients treated with systemic chemotherapy or molecular targeted therapy. Subgroup analysis was planned to compare the surrogate role of TTP in first line therapy and second line therapy.

The correlation between HR of TTP and HR of OS and the correlation between median TTP and median OS were evaluated using spearman rank correlation coefficient (*r*~s~ or rho). Weighted linear regression analysis was also performed to investigate the correlation between these endpoints and to measure the percentage of OS accounted for by TTP (coefficient of determination, *R*^2^). To account for the difference in sample sizes between arms and studies, data were weighted by the number of patients in linear regression analysis.

The correlation between treatment effects on TTP and OS was evaluated based on the log (HR~TTP~) and log (HR~OS~). A linear regression line with 95% CI was used to predict the treatment effects on OS from the observed treatment effects on TTP. Two-sided *P*-values of \<0.05 were considered statistically significant. Statistical analysis was performed with the software package (SAS, version 9.2; SAS Institute, Cary, NC, USA).

Results
=======

Study characteristics
---------------------

Following the systematic literature review, a total of 9 trials were identified with 18 treatment arms and a total of 6318 patients ([Table 1](#tbl1){ref-type="table"}). All studies were phase III trials and evaluated the efficacy of molecular targeted agent. Six studies were performed in systemic chemotherapy naive patients and three studies were conducted in patients who failed sorafenib treatment ([@bib13]; [@bib23], [@bib24]). The median TTP and OS of each treatment arm ranged from 1.4 to 5.5 months and 4.2 to 10.7 months, respectively.

Most patients in the included studies had Eastern Cooperative Oncology Group performance status 0--1, Barcelona Clinic Liver Cancer stage B-C and child-Pugh score A-B ([Table 2](#tbl2){ref-type="table"}). However, the aetiology of HCC was heterogeneous that 18--93% had HBV, 4--30% had HCV and 12--27% had alcoholic liver failure.

TTP as a surrogate marker for OS
--------------------------------

All nine studies reported TTP and three studies reported PFS. Correlation between TTP and OS was analysed using the Spearman rank correlation coefficient. Median OS was associated with median TTP and the *r*~s~ values between TTP and OS were 0.73 (95% CI 0.40--0.89, *P*\<0.001). Using linear regression weighted by sample sizes, *R*^2^ value was 0.41 (95% CI 0.06--0.64, *P*=0.004) and the correlation between OS and TTP was 'OS=5.59+0.87 TTP\' ([Figure 1](#fig1){ref-type="fig"}).

Although TTP can be used as a surrogate marker, their power of predicting OS can be confounded by following treatments. In this analysis, 12 treatment arms from 6 studies was conducted in treatment naïve population and 6 treatment arms in 3 studies evaluated second line treatment. We investigated the association between TTP and OS according to the treatment line. The *r*~s~ values between TTP and OS was 0.59 (95% CI 0.02--0.87, *P*=0.043) and 0.87 (95% CI 0.19--0.99, *P*=0.022), respectively, for first line and second line setting. Corresponding *R*^2^ value was 0.28 (95% CI 0--0.58, *P*=0.075) and 0.80 (95% CI 0.06--0.90, *P*=0.016), respectively.

HR~TTP~ as a surrogate marker for HR~OS~
----------------------------------------

To evaluate whether the reduction in HR of TTP by a specific treatment can predict its reduction in HR of OS, we analysed the association between HR~TTP~ and HR~OS~. In six studies, which compared the efficacy of drug *vs* placebo, placebo was used as a control arm. In three studies, which compared the efficacy of novel molecular targeted agent with sorafenib, sorafenib was defined as a control arm. The *r*~s~ value between Log (HR~TTP~) and Log (HR~OS~) was 0.73 (95% CI 0.12--0.94, *P*=0.024; [Figure 2](#fig2){ref-type="fig"}). The corresponding *R*^2^ was 0.57 (95% CI 0.02--0.77, *P*=0.018) and the regression equation was log (HR~OS~)=0.08+0.52 log (HR~TTP~) indicating that the 10% risk reduction in TTP would yield 5.2% OS risk reduction as reflected in the slope of 0.52. The minimum TTP effect to predict a treatment effect on OS was 0.63, derived from a vertical line that transects the upper 95% CI and an OS of HR equal to 1.

Discussion
==========

Although OS is the gold standard survival endpoint in the clinical trial, it can be affected by sequential treatment after progression and by crossover from control to experimental arms. In addition, OS requires longer follow-up duration. Using surrogate markers such as TTP and PFS can overcome these problems. PFS is defined as the time from randomisation to documented progression or death from any cause. Although PFS is suggested as a reliable surrogate endpoint in many solid tumours, using PFS as a surrogate marker in HCC might confound treatment outcome as 60--80% of patients with HCC have underling liver cirrhosis and many HCC patients die from the progression of liver failure ([@bib21]). TTP, which death before progression is censored as non-progression, has been suggested as reliable surrogate endpoints in HCC ([@bib14]). However, the correlation between TTP and OS has never been evaluated. In the present study, we have investigated that TTP could serve as a surrogate marker for OS based on a relationship between HR~TTP~ and HR~OS~ in 9 phase III studies of advanced HCC. In addition, median TTP was associated with median OS.

The correlation of surrogate endpoints and OS can be influenced by sequential treatment after progression. In a subgroup analysis, the *r*~s~ value and *R*^2^ value between TTP and OS in the first line studies were 0.59 (*P*=0.043) and 0.28 (*P*=0.075). In the second line studies, *r*~s~ value and *R*^2^ value between TTP and OS were 0.87 (*P*=0.022) and 0.80 (*P*=0.016). The correlation between TTP and OS was higher in the second line setting compared with the first line setting. This could be expected as patients enroled in the first line therapy have a higher chance to receive additional treatment after progression compared with those enroled in the second line therapy. In addition, although there is no effective second line systemic chemotherapy besides regorafenib, which has recently been reported, this result may indicate that the survival of HCC patients treated with molecular targeted agent can be influenced by following local therapy or supportive care. However, we could not perform subgroup analysis using HR due to limited number of study included in the study. Although analysis of median data uses each treatment arm as a variates, paired treatment arm is needed in the analysis of HR. Thus, we cannot confirm that the correlation between TTP and OS is higher in the second line setting compared with the first line setting.

There are several limitations in the present study. A reliable surrogate endpoint should be associated with outcome in both individual-level and trial-level measure ([@bib6]). This study was a meta-analysis of previous studies and the association of surrogate endpoint and OS was done in trial-level measure but not in individual-level. Analyses of patient-level data are needed to confirm the surrogacy of TTP for OS. Another limitation of the present study is that only nine clinical trials were included in the meta-analysis. Six studies were performed in first line population and only three studies evaluated second line treatment population. However, our meta-analysis included all randomised controlled phase III trials evaluating the role of molecular targeted therapy in advanced HCC, which have been reported since the advent of sorafenib. In addition, this is the first meta-analysis to evaluate the association of TTP and OS in advanced HCC.

In conclusion, TTP could be used as a surrogate marker in advanced HCC patients treated with molecular targeted therapy. However, the results suggest modest correlation between treatment effects on TTP and OS. Along with individual-level analysis, additional work is needed to confirm our findings.
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![**Correlation between median TTP and median OS.** Circle size is proportional to the number of randomised patients in each arm. The linear equation was median OS=5.59+0.87 median TTP (*R*^2^=0.42, *P*=0.004). Abbreviations: TTP, time to progression; OS, overall survival.](bjc2016322f1){#fig1}

![**Correlation between treatment effects of TTP and OS.** Treatment effects were logarithms of hazard ratios of TTP and OS in each study. Circle size is proportional to the total number of randomised patients in each study. Log scale was used for the *x* axis and *y* axis. The linear equation was log HR~OS~=0.080+0.52 log HR~TTP~ (*R*^2^=0.57, *P*=0.018). The vertical line represents the minimum TTP effect to predict a treatment effect on OS. Abbreviations: HR, hazard ratio; OS, overall survival; TTP, time to progression.](bjc2016322f2){#fig2}

###### Survival results of included studies

  **References**   **Treatment arms**    ***N***    **Line**   **Arms ID**   **Endpoints**   **Median TTP**    **Median OS**       **HR TTP**      **HR OS**
  ---------------- --------------------- --------- ---------- ------------- --------------- ---------------- ------------------ ---------------- --------------
  [@bib15]         Sorafenib             299          1st          1a             TTP        5.5 (4.1--6.9)   10.7 (9.4--13.3)        0.58            0.69
                   Placebo               303                       1b             TTP        2.8 (2.7--3.9)    7.9 (6.8--9.1)     (0.45--0.74)    (0.55--0.87)
  [@bib9]          Sorafenib             150          1st          2a             TTP        2.8 (2.6--3.6)    6.5 (5.6--7.6)         0.57            0.68
                   Placebo               76                        2b             TTP        1.4 (1.4--1.6)    4.2 (3.8--5.5)     (0.42--0.79)    (0.50--0.93)
  [@bib13]         Brivanib              263          2nd          3a             TTP             4.2               9.4               0.56            0.89
                   Placebo               132                       3b             TTP             2.7               8.2           (0.42--0.76)    (0.69--1.15)
  [@bib12]         Brivanib              577          1st          4a             TTP        4.2 (4.1--4.3)   9.5 (8.3--10.6)         1.01            1.07
                   Sorafenib             578                       4b             TTP        4.1 (3.1--4.2)   9.9 (8.5--11.5)     (0.88--1.16)    (0.94--1.23)
  [@bib10]         Sunitinib             530          1st          5a             TTP        4.1 (3.2--4.1)    7.9 (7.4--9.2)         1.13            1.30
                   Sorafenib             544                       5b             TTP        3.8 (2.9--4.2)   10.2 (8.9--11.4)    (0.98--1.31)    (1.13--1.50)
                   Sunitinib                                                      PFS        3.6 (2.8--4.1)    7.9 (7.4--9.2)         1.13            1.30
                   Sorafenib                                                      PFS        3.0 (2.8--4.0)   10.2 (8.9--11.4)    (0.99--1.30)    (1.13--1.50)
  [@bib23]         Everolimus            362          2nd          6a             TTP        3.0 (2.8--4.0)    7.6 (6.7--8.7)         0.93            1.05
                   Placebo               184                       6b             TTP        2.6 (1.5--2.8)    7.3 (6.3--8.7)     (0.75--1.15)    (0.86--1.27)
  [@bib8]          Linifanib             514          1st          7a             TTP        5.4 (4.2--5.6)   9.1 (8.1--10.2)         0.76            1.05
                   Sorafenib             521                       7b             TTP        4.0 (2.8--4.2)   9.8 (8.3--11.0)     (0.64--0.90)    (0.90--1.22)
                   Linifanib                                                      PFS        4.2 (4.1--5.4)   9.1 (8.1--10.2)        0.813            1.05
                   Sorafenib                                                      PFS        2.9 (2.8--4.0)   9.8 (8.3--11.0)    (0.697--0.948)   (0.90--1.22)
  [@bib25]         Sorafenib+Erlotinib   362          1st          8a             TTP             3.2               9.5               1.14            0.93
                   Sorafenib+Placebo     358                       8b             TTP             4.0               8.5           (0.94--1.37)    (0.78--1.11)
  [@bib24]         Ramucirumab           283          2nd          9a             TTP        3.5 (2.8--4.5)   9.2 (8.1--10.6)         0.59            0.87
                   Placebo               282                       9b             TTP        2.6 (1.6--2.8)    7.6 (6.0--9.3)     (0.49--0.72)    (0.72--1.05)
                   Ramucirumab                                                    PFS        2.8 (2.7--3.9)   9.2 (8.1--10.6)         0.63            0.87
                   Placebo                                                        PFS        2.1 (1.6--2.7)    7.6 (6.0--9.3)     (0.52--0.75)    (0.72--1.05)

Abbreviations: HR=hazard ratio; OS=overall survival; PFS=progression-free survival; TTP=time to progression.

###### Baseline characteristics of included studies

                                         **ECOG PS**   **BCLC stage**   **Child-Pugh score**   **HCC aetiology**                                                   
  ---------- --------------------- ----- ------------- ---------------- ---------------------- ------------------- ----- ----- ----- ------ ----- ---- ----- ----- -----
  [@bib15]   Sorafenib             290   54%           38%              8%                     0%                  18%   82%   0%    95%    5%    0%   19%   29%   26%
             Placebo               303   54%           39%              7%                     0%                  17%   83%   0%    98%    2%    0%   18%   27%   26%
  [@bib9]    Sorafenib             150   25%           69%              5%                     N/A                 N/A   95%   N/A   97%    3%    0%   71%   11%   N/A
             Placebo               76    28%           67%              5%                     N/A                 N/A   96%   N/A   97%    3%    0%   78%   4%    N/A
  [@bib13]   Brivanib              263   57%           39%              4%                     3%                  9%    87%   1%    92%    7%    1%   39%   28%   23%
             Placebo               132   61%           35%              4%                     1%                  14%   85%   0%    91%    9%    0%   34%   27%   27%
  [@bib12]   Brivanib              577   64%           36%              0%                     6%                  17%   77%   0%    92%    8%    0%   44%   20%   18%
             Sorafenib             578   61%           39%              0%                     5%                  17%   78%   0%    92%    8%    0%   45%   21%   14%
  [@bib10]   Sunitinib             530   53%           47%              0%                     0%                  13%   87%   0%    100%   0%    0%   55%   21%   17%
             Sorafenib             544   53%           47%              0%                     0%                  16%   84%   0%    100%   0%    0%   53%   22%   15%
  [@bib23]   Everolimus            362   59%           36%              5%                     0%                  14%   86%   0%    98%    2%    0%   25%   26%   18%
             Placebo               184   57%           40%              3%                     0%                  14%   86%   0%    99%    1%    0%   28%   23%   25%
  [@bib8]    Linifanib             514   63%           37%              0%                     0%                  16%   84%   0%    94%    6%    0%   54%   25%   13%
             Sorafenib             521   66%           34%              0%                     0%                  20%   80%   0%    95%    5%    0%   53%   25%   12%
  [@bib25]   Sorafenib+Erlotinib   362   61%           39%              0%                     0%                  17%   83%   0%    100%   0%    0%   34%   30%   N/A
             Sorafenib+Placebo     358   60%           40%              0%                     0%                  13%   87%   0%    100%   0%    0%   37%   24%   N/A
  [@bib24]   Ramucirumab           283   56%           44%              0%                     0%                  12%   88%   0%    56%    44%   0%   35%   27%   N/A
             Placebo               282   54%           46%              0%                     0%                  12%   88%   0%    54%    46%   0%   36%   27%   N/A

Abbreviations: BCLC=Barcelona Clinic Liver Cancer; ECOG PS=Eastern Cooperative Oncology Group performance status; HBV=hepatitis B virus; HCC=hepatocellular carcinoma; HCV=hepatitis C virus; *N*=number; N/A=not available.
